• Vitrafy's cryopreservation ecosystem exceeded regulatory and quality guidelines
• 3% DMSO no-wash protocol achieved 94% post-thaw recovery
• No-wash solution enables platelet stockpiling and deployment in constrained settings

Vitrafy Life Sciences Limited announced the successful completion of the Phase II in-vitro study with the United States Army Institute of Surgical Research (USAISR). The study evaluated Vitrafy's cryopreservation ecosystem across all tested protocols, demonstrating superior performance compared to existing regulatory and quality guidelines for platelet use. The 3% DMSO no-wash protocol achieved an average 94% post-thaw recovery, outperforming other protocols in critical criteria. This no-wash solution removes the need for specialized processing, enabling platelet stockpiling and deployment in regional hospitals, emergency response, and battlefield settings. The results validate Vitrafy's potential to address the market gap for cryopreserved platelets.

Vitrafy and USAISR plan to present Phase II findings at international scientific conferences and aim for FDA medical device registration in the first half of FY2027.